Podcasts about zepbound

Linktree - our favorite links (https://linktr.ee/dinosaurmonkeyfarts)NEW: Need GLP-1 Care? Join me at Belle! Use code Podcast at checkout to save 15% right now, and I run a support group there weekly!https://link.joinbelle.com/podcastNEW: Cozy Butter GLP-1 Community! Join Freehttps://cozybutter.com/Need 1-on-1 GLP-1 Journey Support? Book time with Kim and use code Cozy20 to save at checkout. Calendar Link https://calendly.com/theplussidez/kim?back=1&month=2026-09 We Built a Free GLP-1 Support Community | Cozy Butter + On The PenLooking for a GLP-1 support group or community where you can connect with other patients without diet culture, spam, or an algorithm deciding what you see? We built one.Cozy Butter is a free, patient-led GLP-1 community created by Kim Carlos of The Plus SideZ Podcast and Amanda Bonello of GLP-1 Studio. It was built for people taking or considering medications like Ozempic, Wegovy, Mounjaro, and Zepbound who want practical tools, education, peer support, events, and real conversations about living with obesity and metabolic disease.We sat down with Dave Knapp of On The Pen to share how Cozy Butter started, how Kim and Amanda met through GLP-1 advocacy, and why we believe patients need more support between appointments.We talk about GLP-1 peer support, obesity as a chronic disease, weight stigma, food noise, patient advocacy, health coaching, self-advocacy, GLP-1 tools, medication access, expert Q&As, community events, and what we hope to build next.JOIN COZY BUTTER FREEhttps://cozybutter.com/Anyone who joins in September 2026 becomes a Cozy Butter Founding Member. The community is free to join, and current sessions and classes are free for Founding Members. Founding Members will also receive a permanent discount on future paid sessions and classes.MORE FROM KIM CARLOSKim's favorite links:https://linktr.ee/dinosaurmonkeyfartsThe Plus SideZ Podcast:https://theplussidez.net/YouTube:https://www.youtube.com/@theplussidezInstagram:https://www.instagram.com/dmfkimonglp1/TikTok:https://www.tiktok.com/@dmfkimNeed GLP-1 care? Join Kim at Belle and use code Podcast to save 15% at checkout:https://link.joinbelle.com/podcastBook 1-on-1 GLP-1 journey support with Kim and use code Cozy20 at checkout:https://calendly.com/theplussidez/kim?back=1&month=2026-09FOLLOW AMANDA BONELLOGLP-1 Studio:https://glp1studio.com/Instagram:https://www.instagram.com/amanda.bonell0/TikTok:https://www.tiktok.com/@amanda.bonelloGLP-1 patient advocacy tools:https://glp1strong.com/GLP-1 laws and news:https://glp1laws.com/FOLLOW DAVE KNAPP / ON THE PENOn The Pen:https://onthepen.com/On The Pen GLP-1 News on Apple Podcasts:https://podcasts.apple.com/us/podcast/on-the-pen-glp-1-news/id1725737068ABOUT COZY BUTTERCozy Butter is a GLP-1 community built around patients supporting patients. Members can connect with peers, attend live events and support groups, access practical GLP-1 tools, learn from experts, and find support throughout their GLP-1 journey.https://cozybutter.com/This conversation is for education and general information only and does not replace medical advice from your healthcare provider.#GLP1 #GLP1Community #ObesityCare_________________________________________________________________________Join this channel to get access to perks:https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join_________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovySend us Fan Mail!The Podcast Promo Ad Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Hour 1 of A&G features... Jack's Zepbound issues, Che D Vance, 60 Minutes & AI Katie Green's Headlines! Conflict in the Middle East Freedom Loving Quote of the Day! See omnystudio.com/listener for privacy information.

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound have gone from relatively niche diabetes medications to one of the biggest (and most controversial) stories in health and wellness.As you may have noticed, I've taken a bit of a hiatus from the podcast the past couple of months while I've been recovering from a SCAD heart attack.Today, I'm back with a brand new conversation about weight loss drugs with Ragen Chastain, a researcher, writer, speaker, and board-certified patient advocate who has spent more than 20 years examining the intersections of weight science, weight stigma, and healthcare. She brings a research- and statistics-informed perspective to a conversation that is often dominated by pharmaceutical marketing, influencer anecdotes, and very simplified claims about what these medications do.We do a deep dive into GLP-1 medications, weight loss, food noise, hunger, weight stigma, and what we actually know about the safety and long-term effects of these drugs.In this episode, we get into:* Ragen's journey from dieting and doing her own literature review to becoming a researcher and advocate in the weight-inclusive healthcare space* What we know about the failure of long-term weight-loss interventions* Weight-inclusive healthcare and why it shouldn't depend on whether we believe people can or cannot lose weight* How GLP-1 medications work, including their effects on blood sugar, gut motility, digestion, and hunger* The difference between diabetes dosing and the higher doses used for weight loss* What “food noise” actually means (and what it doesn't mean)* How diet culture and restriction can affect hunger and thoughts about food* The medicalization of hunger* Why the same symptoms can be interpreted and treated differently depending on the size of the person experiencing them* Weight stigma in healthcare and the assumption that weight loss is the answer to an enormous range of health concerns* What we know and don't know about the long-term safety of GLP-1 medications* Why research on a medication at one dose cannot automatically answer questions about that medication at another dose* Study dropout and what can get lost when we look only at headlines, abstracts, and conclusions* Conflicts of interest in pharmaceutical research* Concerns about the quality and transparency of long-term safety data* What happens when medications designed to suppress hunger are used in people whose bodies are otherwise regulating blood sugar normallyThis is part one of the conversation. In part two (releasing next week) we'll dig further into weight regain, body composition, how GLP-1 research is presented to the public, the explosion of claims that these medications can treat everything from cardiovascular disease to mental health concerns, pharmaceutical influence on healthcare providers, and what you can actually do when a doctor recommends a GLP-1.Apply for Abbie's Group Membership:If you're looking for community and continued learning, apply for Abbie's monthly membership: https://www.abbieattwoodwellness.com/circle-monthly-group. We meet every other Thursday, and have a private online space for ongoing conversations between sessions.Enjoying this podcast? Please support the show on Substack for bonus episodes, community engagement, and access to "Ask Abbie" at abbieattwoodwellness.substack.com/subscribeFind more resources from Ragen:Substack: https://weightandhealthcare.substack.com/Instagram: https://www.instagram.com/ragenchastain/?hl=en  This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit abbieattwoodwellness.substack.com/subscribe

Just started a GLP-1 and wondering what you're actually supposed to do now?Maybe you just took your first dose of Ozempic, Wegovy, Mounjaro, or Zepbound. Maybe you're a few weeks in and wondering why you don't feel dramatically different yet. Or maybe your prescription is sitting in the refrigerator and you're trying to figure out how to do this "right" from day one.This episode is your GLP-1 beginner's guide.As both a Registered Dietitian who works with GLP-1 users and someone who has been taking a GLP-1 myself since 2022, I'm walking you through the seven things I want you to focus on when you're starting your medication.We're talking realistic expectations, nutrition, protein, hydration, constipation, strength training, tracking your progress, and why comparing your first month to someone else's TikTok transformation is one of the fastest ways to make yourself miserable.You do NOT need to have your entire GLP-1 journey figured out during your first week.Let's start with what actually matters.In This Episode, You'll LearnWhat to focus on when you first start a GLP-1Why you may not notice dramatic changes after your first injectionWhy your first few weeks don't determine whether your GLP-1 is "working"Why eating as little as possible should never be the goalHow to start prioritizing protein from the beginningWhy hydration, fiber, and bowel habits deserve your attention earlyWhy strength training matters during GLP-1 weight lossHow to think about preserving muscle while losing weightWhat to track besides the number on the scaleWhy food noise, hunger, energy, strength, digestion, and habits are all valuable informationHow social media can completely distort your expectations of GLP-1 weight lossWhy someone else's progress is not a benchmark for your bodyWhen to reach out to your healthcare team for additional support

Gabe and Annie Rench are back for round two on the biggest trend in health and fitness right now: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. A year after their first Ozempic episode blew up, they revisit the topic with fresh eyes — why so many people (maybe one in three women, by their guess) feel like they have no other option, what the British Medical Journal's newest research says about weight regain after stopping, and why "just eat less" is the most reductionist advice in modern medicine.

Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about Retatrutide, the third-generation injectable making waves as the most powerful weight-loss drug studied yet. It targets three hormone pathways at once instead of just one or two, and early trial participants have lost staggering amounts of weight, some over 30 percent of their body weight. But is more always better? Jenn breaks down how this triple mechanism works in the body, what the research shows so far, and why it might finally help the roughly 10 percent of people who never responded to earlier GLP-1s. Still, she has been raising the same concerns since Ozempic first came onto the scene, and this new drug is no exception. Is Retatrutide the breakthrough the weight loss world has been waiting for, or just a stronger version of the same unanswered questions? Tune in to hear Jenn's full take. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/ RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramOzempicAmerican Diabetes Association Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMCGlucagon | HormonesInternational Journal of Molecular SciencesHyperglycemia vs. Hypoglycemia: Differences in Causes and Symptoms - GoodRxGlucagon Control on Food Intake and Energy Balance - PMCLilly Phase 3 StudyComparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials - ScienceDirectLilly - RetatrutideWhat Is Osteoarthritis? Causes, Symptoms, and Treatments - GoodRxPotential Retatrutide Benefits You Should Know About - GoodRxClinical TrialsStudy Details | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | ClinicalTrials.govClinical TrialsStudy Details | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ClinicalTrials.govClinical TrialsNCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | ClinicalTrials.gov11 GLP-1 Side Effects You Should Know About - GoodRxTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine Counterfeit DrugsPeptides for Weight Loss: What They Are and How They Work - GoodRxJenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Retatrutide, Glp 1, Gip, Glucagon, Weight Loss, Ozempic, Wegovy, Mounjaro, Zepbound, Tirzepatide, Semaglutide, Insulin Sensitivity, Gastric Emptying, Appetite Suppression, Blood Sugar Control, A1c, Glycated Hemoglobin, Liver Steatosis, Fatty Liver Disease, Diabetic Kidney Disease, Type 2 Diabetes, Metabolic Dysfunction, Cardiovascular Risk, Osteoarthritis, Bone Density, Muscle Loss, Body Composition, Clinical Trials, Phase Three Trials, Injectable Medication, Weight Loss Drug, Pharmaceutical Intervention, Hunger Hormone, Satiety, Nausea, Constipation, Gastrointestinal Side Effects, Compounding Pharmacy, Counterfeit Medication, Obesity Treatment, Incretin Hormone, Retatrutide Weight Loss Results, Third Generation Glp 1 Medication

In this inspiring episode of The Confidence Doc, host Dr. Vinaya Rednam sits down with content creator and patient Jenny Espino (@jennyloseswithzep) to discuss her 120-pound weight loss journey . Jenny opens up about her past experience with bariatric surgery, dealing with weight regain after a major back injury, and how starting a GLP-1 medication (Zepbound) finally helped turn off "food noise" and get her life back . She also shares her honest experience undergoing skin removal surgery with Dr. Rednam—from managing pre-op anxiety to navigating a surprisingly smooth recovery—and how reaching her goal weight has allowed her to embrace a new lifestyle, rediscover her fashion style, and be fully active for her family . Key Discussion Points / Show Notes: Jenny's 120-lb Weight Loss Journey: How documenting her very first Zepbound shot sparked a supportive online community . Overcoming Setbacks: Navigating weight regain after a 2006 bariatric surgery due to a 2020 back injury . Turning Off "Food Noise": How GLP-1 medication helped eliminate fast food addiction and provided a tool for sustainable control . Skin Removal & Recovery: Jenny's experience undergoing post-weight loss skin removal surgery, addressing fears versus the reality of recovery, and managing scars . Life on Maintenance: Transitioning to goal weight, finding personal style through shopping, and being an active mom . If you loved this episode, don't forget to hit that heart button, like, and subscribe to The Confidence Doc! Sharing this video or leaving a review helps us reach more people who need to hear these inspiring stories. Let us know your favorite takeaway in the comments below!

Send us Fan MailIs weight loss really a matter of willpower—or have we misunderstood the biology behind hunger?Bracha Banayan, FNP-BC, joins Joey Pinz to explore the rapidly evolving world of GLP-1 medications, metabolic health, food noise, cravings, and sustainable weight loss. Drawing from her clinical experience and personal journey, Bracha explains why traditional advice to “eat less and try harder” often fails—and why that failure should not be confused with laziness.The conversation moves beyond weight loss into the brain's reward system and the potential relationship between GLP-1s, alcohol, smoking, shopping, and other compulsive behaviors. Bracha also explains why these medications should never become an excuse to ignore strength training, muscle preservation, nutrition, and lasting habit change.The discussion becomes deeply personal as Bracha shares how remedial classes shaped her persistence, why entrepreneurship taught her difficult lessons about leadership, and how leaving Orthodox Judaism led her toward a broader spiritual path. She also reveals how egg freezing changed her relationship with fear, courage, vulnerability, and regret.This is a provocative conversation about biology, personal responsibility, longevity, identity, and what sustainable transformation truly requires.Top Three Highlights

What should your plate actually look like when you're taking a GLP-1?You've heard you need protein. You've heard you need fiber. You know eating as little as possible isn't the goal. But when it comes time to actually make breakfast, lunch, or dinner...what are you supposed to put together?In this episode of Your GLP-1 Bestie, Registered Dietitian Gianna Beasley breaks down a simple, flexible framework for building balanced meals while taking medications like Ozempic, Wegovy, Mounjaro, and Zepbound.We're talking protein, produce, carbohydrates, and fats—and why you don't need to perfectly portion your plate, weigh your food, track every macro, or force yourself to eat a giant pile of vegetables when your appetite is already low.You'll also hear real-life meal examples and learn how to adjust this framework for smaller appetites, early fullness, nausea, busy days, and those times when nothing sounds particularly good.Because a balanced plate should make eating on a GLP-1 simpler, not more stressful.In This Episode, You'll LearnA simple framework for building balanced meals on a GLP-1Why a balanced plate is a framework—not a rigid formulaWhy protein is often a helpful place to startHow fruits and vegetables fit into your mealsWhy carbohydrates absolutely still belong on your plateThe role dietary fat plays in a balanced mealWhy you don't need four separate foods to "check every box"Real-life examples of balanced GLP-1 breakfasts, lunches, and dinnersHow to modify your plate when you get full quicklyWhy the traditional "half your plate vegetables" advice may not work for everyone with a significantly reduced appetiteWhat to eat on days when your appetite is especially lowHow to stop turning nutrition recommendations into another set of diet rulesThe 10 second meal check method

Can GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound do more than support weight loss? In this episode of Reversing Hashimoto's, we explore the emerging connection between GLP-1 therapy, metabolic health, inflammation, insulin resistance and autoimmune thyroid disease.We discuss what the current research actually shows about GLP-1 medications and inflammation, including their effects on markers such as CRP, while separating promising science from social-media hype. Could improving obesity, insulin resistance, fatty liver and metabolic inflammation create a healthier environment for someone with Hashimoto's?You'll also learn why GLP-1s should not currently be considered a proven treatment for Hashimoto's, why there isn't enough evidence to say they reliably reduce TPO or thyroglobulin antibodies, and what to consider if you take levothyroxine while losing significant weight.The episode also covers muscle preservation, protein intake, strength training, nutrition, thyroid monitoring, supplements, peptides and the thyroid-cancer warning associated with GLP-1 medications.Timestamps:00:00 – GLP-1s & Hashimoto's: The Big Question02:00 – Hashimoto's Is More Than a Thyroid Problem05:00 – GLP-1s and Inflammation08:00 – Metabolic Inflammation & Hashimoto's11:00 – What the Research Actually Shows15:00 – Who May Benefit From GLP-1 Therapy?18:00 – Thyroid Function & Levothyroxine21:00 – Protecting Muscle While Losing Weight25:00 – Nutrition, Protein & Strength Training29:00 – Supplements & Experimental Peptides33:00 – GLP-1s & Thyroid Cancer Concerns37:00 – Can GLP-1s Reduce Thyroid Inflammation?41:00 – Practical Hashimoto's Approach & Final Takeaway#Hashimotos #GLP1 #ThyroidHealth #AutoimmuneDisease #ThyroidInflammation #Ozempic #Wegovy #Mounjaro #Zepbound #MetabolicHealth #InsulinResistance #ThyroidHealth

Eli Lilly is testing a new GLP-1 called brenipatide in phase three trials, and weight loss isn't even the main focus, researchers are watching it for alcohol use disorder, opioid addiction, bipolar disorder, and IBS. Chalene Johnson also breaks down a new Yale University study on why the hunger hormones ghrelin and leptin roar back the moment someone stops taking a GLP-1. Then Chalene calls out an Instagram account called Baddie Bethany (also posting as Baddie Betty on Facebook), nearly a million followers and Instagram is rolling out a brand new AI content label. She also flags an AI "Dr. Chen" wellness account blending real health facts with false ones to earn trust. Plus, five new health devices she's watching, including a toilet sensor called Throne, an AI skin scanner called SkinBit, and a caregiving wearable from the founders of Fitbit. Topics discussed: Eli Lilly, brenipatide, Zepbound, Yale University, ghrelin, leptin, berberine, Baddie Bethany, Baddie Betty, Dr. Chen, Chen Family Wellness, Carrie Sisson, Instagram, Throne, SkinBit, Prenuvo, 3D Radiology, Eight Sleep, Apple, Fitbit, Lufu, Lindsey Clancy trial.   Join Chalene on Patreon her private podcast to hear all the latest on the Penthouse Drama and the Session with a Renowned Pet Psychic  

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have reshaped the weight-loss landscape almost overnight — but the way they're often prescribed leaves people under-fueled, losing muscle, and going it alone. In this episode of The Coaching Lab, host Leigh Baker sits down with National Board Certified Health & Wellness Coach Erin Chain and triple-board-certified physician Dr. Sheri Poznanovic of Optin Health & Nutrition to unpack what's really happening in the GLP-1 era — and where health and wellness coaching fits into the care plan.Together they explore why so many people on GLP-1s aren't eating or hydrating enough, how rapid weight loss can mask dangerous muscle mass loss, and why a "prescribe-and-disappear" model falls short. Dr. Poznanovic explains the multidisciplinary approach the Obesity Medicine Association recommends — combining medication, nutrition, body composition testing, VO2 max assessment, and coaching — while Erin shares real-world stories of clients navigating low energy, food noise, protein gaps, medication interactions, and the stigma of being on a GLP-1.Whether you're a coach, a clinician, an employer weighing GLP-1 coverage, or someone considering these medications yourself, this conversation offers a grounded, human look at doing weight loss in a way that protects strength, health span, and quality of life — not just the number on the scale.In this episode: • Why coaching alongside a GLP-1 changes outcomes • The under-eating and muscle-loss risks no one warns you about • Protein targets, carbs, and why "anti-carb" advice backfires • Body composition and VO2 max testing in weight management • Medication interactions as you lose weight • Navigating stigma and the joy of food • What employers and coaches should know before adding GLP-1sCoaches: Explore CE credits at catalystcoachinginstitute.com Employers: Learn about Catalyst Coaching's GLP-Whole offering — results@catalystcoaching360.com Join us this fall at the Rocky Mountain Coaching Retreat & Symposium: catalystcoachinginstitute.com/retreatInfo re earning your health & wellness coaching certification, annual Rocky Mountain Coaching Retreat & Symposium & more via https://www.catalystcoachinginstitute.com/ Best-in-class coaching for Employers, EAPs & wellness providers https://catalystcoaching360.com/Tap into the home of the (freely available) Not Done Yet! articles on unlocking life's 2nd half here.YouTube Coaching Channel https://www.youtube.com/c/CoachingChannelContact us: Results@CatalystCoaching360.comTwitter: @Catalyst2ThriveWebsite: CatalystCoaching360.comIf you are a current or future health & wellness coach, please check out our Health & Wellness Coaching Community on Facebook: https://www.facebook.com/groups/278207545599218.  This is a wonderful group if you are looking for encouragement, ideas, resources and more. 

Is gaining weight really the worst thing that can happen?Obviously, there are a million worse things. But for me, the answer is still kind of yes—and not because of the number on the scale.At my highest weight, the biggest loss wasn't clothing size or how I looked. It was my quality of life. My anxiety got worse. I dealt with agoraphobia and depression. I avoided things, sat on the sidelines, and slowly made my world smaller.After gaining a few pounds back this summer, I had a wake-up call. I'm nowhere near where I was, but I also know I never want to go back to living that way.This episode is about what weight gain can quietly take from you—and why I'm choosing to stop that slide now.Irresistible Links:Show Notes

Are you actually eating enough on your GLP-1?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may be eating significantly less than you did before—and that's partly the point. But there's an important difference between having a reduced appetite and not adequately nourishing your body.Maybe you're rarely hungry anymore. Maybe you get to the end of the day and realize you've barely eaten. Or maybe the scale is moving quickly, so you've assumed that eating as little as possible means your medication is "working."In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down how to recognize when your intake may be too low, why eating enough still matters during weight loss, and practical ways to nourish yourself when your appetite has practically disappeared.Because your GLP-1 may reduce your appetite—but it doesn't reduce your body's need for nutrition.In this episode, you'll learn:How to tell if you may not be eating enough on a GLP-1Why having no appetite isn't necessarily the goalSigns that may warrant a closer look at your nutritionWhy fatigue, weakness, dizziness, constipation, and hair changes can sometimes be clues—but can also have other causesWhy eating only once or twice a day can make meeting your nutrition needs difficultWhy faster weight loss isn't automatically better weight lossHow under-fueling can affect energy, muscle, recovery, and nutrient intakeWhy protein isn't the only nutrient that mattersHow to create regular eating opportunities when hunger cues are quietEasy foods to reach for when you don't feel like eatingWhen low appetite or GI side effects deserve a conversation with your healthcare providerEmerging evidence and professional guidance increasingly emphasize maintaining adequate protein, fiber, micronutrients, hydration, and muscle health as intake falls during GLP-1 treatment.

The FDA just expanded Mounjaro's label to include reducing the risk of major adverse cardiovascular events, and the headline is easy to love and easy to misunderstand. We slow it down and translate what the approval actually means for people living with type 2 diabetes, especially those worried about heart attack, stroke, and cardiovascular death.We unpack the exact endpoint behind the claim: MACE, which combines cardiovascular death, non-fatal heart attack, and non-fatal stroke, and we clarify what it is not saying (no, it is not “erasing plaque” or curing atherosclerotic cardiovascular disease). We also explain the real-world nuance around branding and indications: Mounjaro and Zepbound are both tirzepatide, but FDA labels are population-specific, and that can affect clinical decisions and insurance coverage.Then we walk through the Surpass-CVOT cardiovascular outcomes trial in plain English. The key twist is the comparator: tirzepatide was tested against Trulicity (dulaglutide), an active GLP-1 medication with known heart benefit, not placebo. That's why understanding noninferiority vs superiority matters so much. We talk hazard ratios, absolute vs relative risk, and the surprising finding that bigger weight loss and a larger A1C drop did not translate into statistically superior cardiovascular outcomes during the study window.We close with practical guidance and a list of questions you can bring to your own checkup, including whether you have established cardiovascular disease, what makes you “high risk,” whether other cardioprotective meds are already doing the job, how dose changes could affect insulin or blood pressure meds, and what it will actually cost. If you found this helpful, subscribe, share the show with someone managing diabetes risk, and leave us a review so more people can find clear medical context.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

You cannot open your phone anymore without hearing about Ozempic, Wegovy, Mounjaro, Zepbound, retatrutide, and before-and-after transformations. One person says GLP-1s are the greatest thing ever. Another says they are going to destroy your health. As usual, the truth is somewhere in the middle. In this episode, I break down GLP-1s specifically through the lens of perimenopause and menopause, because midlife women are dealing with a completely different metabolic landscape. Estrogen is changing. Muscle is easier to lose. Insulin sensitivity may be shifting. Sleep is falling apart. Belly fat is showing up where it never used to. And simply telling a woman to eat less and exercise more is not a strategy. We talk about where GLP-1s can be incredibly useful, why HRT and GLP-1s are not interchangeable, and why protecting muscle has to be one of your top priorities if you are using these medications. I also get into dosing, microdosing, appetite suppression, thyroid and hormone optimization, realistic weight-loss rates, and why the goal should never be to get as skinny as possible as fast as possible. The goal is to lose fat while preserving muscle, supporting hormones, improving metabolic health, and having an actual plan for what happens after the weight comes off. In this episode, we cover: Why menopause changes fat distribution and increases abdominal fat for many women How declining estrogen, muscle loss, sleep, and insulin resistance affect midlife weight How GLP-1 medications work beyond simple appetite suppression Why GLP-1s are not "cheating" Why GLP-1 therapy does not replace HRT Whether HRT and GLP-1s can be used together Why muscle loss is one of the biggest concerns with GLP-1 use Why protein and resistance training matter so much Why having no appetite does not mean your dose is perfect Microdosing versus standard GLP-1 dosing Why increasing your dose too quickly can backfire What a realistic rate of weight loss can look like The importance of thyroid and hormone optimization when weight loss stalls Why maintenance needs to be part of the plan from day one Who This Episode Is For This episode is for women in perimenopause and menopause who are considering a GLP-1, already taking one, or wondering whether these medications could help with stubborn midlife weight gain. It is especially for women who want to lose fat without sacrificing muscle, energy, hormones, bone health, or long-term metabolic health. If you are confused by the microdosing hype, worried about muscle loss, unsure whether you should do HRT or a GLP-1 first, or wondering why your weight loss has stalled even though you are taking medication, this episode is for you.     Sponsors BEAM: Use coupon code HORMONE for 20% off your order Try the power of copper peptides on your skin today and get 20% off your order with coupon code km20 here.     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are everywhere right now. Maybe you're curious about them. Maybe you're already taking one. Or maybe part of you feels like using medication would somehow be "cheating." In this episode, Dara takes a step back from the debate and looks at the bigger picture. What do GLP-1 medications actually do? Can they reduce food noise? And if they quiet your desire for food, does that mean they've resolved the reason you were turning to food in the first place? Dara shares research and perspectives from several medical and psychological professionals, including differing opinions about who may benefit most from GLP-1 medications, what happens when the medication is stopped, and how appetite suppression could potentially interact with perfectionism and rigid thinking. But this isn't a yes-or-no episode about whether you should take a GLP-1. Instead, Dara wants you to ask better questions. If the food noise disappeared tomorrow, would the rest of your life feel resolved? What would you finally believe about yourself if you reached your goal weight? And why does that belief have to wait until you lose the weight? Dara also explores the connection between emotional eating, food noise, over-hunger, and over-desire—and why understanding the why behind your eating patterns may be just as important as changing the behavior itself. In this episode, you'll learn: What GLP-1 medications actually do to appetite and food noise Why quieting food noise isn't necessarily the same as resolving its underlying cause Why doctors and researchers don't all agree about GLP-1 medications How emotional eating can be connected to suppressing or avoiding difficult emotions The difference between over-hunger and over-desire How perfectionism and all-or-nothing thinking may factor into your relationship with food The questions to ask yourself before deciding whether a GLP-1 is right for you Important: This episode is for education and personal reflection, not medical advice. Talk with your healthcare provider about whether a GLP-1 medication is appropriate for you. If you're considering a GLP-1—or you're already taking one and still wondering what's really driving your relationship with food—Dara invites you to book a free diagnosis call to explore your unique pattern. Book your call HERE. Subscribe for more episodes on emotional eating!

Greg Kelly shares personal updates and political commentary, beginning with his significant weight loss journey using the medication Zepbound. He transitions into a critique of Michael Cohen, questioning the legal validity of Cohen's past statements and calling for a formal apology to the Trump family. Greg defends Donald Trump's handling of classified documents by citing the Presidential Records Act and praising Eric Trump's intelligence and character.

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks down two of the biggest GLP-1 stories of the week: why most states are opting out of the Trump administration's new Medicaid obesity-drug coverage model, and why employers are preparing to cut GLP-1 coverage in 2027.We also dig into the growing conversation around GLP-1 microdosing after Real Housewives of Orange County star Emily Simpson described using a lower-frequency maintenance strategy after losing around 50 pounds. Could lower-dose or intermittent GLP-1 therapy eventually become a legitimate maintenance tool? Could it help lower long-term healthcare costs? And could earlier, lower-intensity treatment eventually become a form of prophylaxis against obesity-related disease?This episode covers Medicaid GLP-1 coverage, the BALANCE model, Zepbound coverage, Wegovy coverage, employer insurance changes, compounded GLP-1 access, GLP-1 microdosing, obesity maintenance, semaglutide, tirzepatide, metabolic disease prevention, obesity medicine, healthcare costs, and the future of GLP-1 treatment.If you take Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, compounded tirzepatide, or simply follow the rapidly changing world of obesity medicine, this is a conversation you need to hear.Subscribe to On The Pen for breaking GLP-1 news, obesity medicine updates, access and insurance coverage news, new weight-loss drugs, clinical research, and patient advocacy.More from On The Pen: https://linktr.ee/manonthemounjaro#GLP1 #Ozempic #Wegovy #Mounjaro #Zepbound #Semaglutide #Tirzepatide #Microdosing #ObesityMedicine #WeightLoss #Medicaid #HealthInsurance #CompoundedGLP1 #Obesity #GLP1News

Orforglipron is a new oral GLP-1 medication for weight loss, and many patients are asking how it compares to injectable options like Ozempic, Wegovy, and Zepbound. In this episode, Dr. Greg Jones is joined by Dr. Kris Wusterhausen to explain what orforglipron is, how it works, and where it may fit in the future of medical weight management.They discuss why this oral GLP-1 is different from traditional peptide-based therapies, including how small-molecule medications may affect absorption, dosing convenience, and patient accessibility. The conversation also covers what current research shows about weight-loss results, blood sugar changes, cardiovascular markers, side effects, contraception considerations, surgical precautions, and long-term use.If you are curious about orforglipron, oral GLP-1 medications, weight-loss drugs, metabolic health, muscle preservation, or how these therapies compare with injectable GLP-1 options, this episode offers a practical, clinically informed overview of the benefits, limitations, and unanswered questions.Get 10% off your first order at Dr. Jones Supplement Store when you join the email list. https://drjonessupplements.com/

Ralph in Virigina called Mark to tell him about how Zepbound was the best weight-loss drug that he took. Tony in Old Bridge, NJ, called in to talk about how Data Centers going underground may be a possibility.

Ralph in Virigina called Mark to tell him about how Zepbound was the best weight-loss drug that he took. Tony in Old Bridge, NJ, called in to talk about how Data Centers going underground may be a possibility. See omnystudio.com/listener for privacy information.

What should you actually buy at the grocery store when you're taking a GLP-1?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and you've ever found yourself wandering the grocery store wondering what foods you should be eating, this episode is for you.As a Registered Dietitian and GLP-1 user myself, I'm taking you grocery shopping with me! We're walking aisle by aisle through the foods I keep on hand to make eating well on a GLP-1 simpler, more satisfying, and much more realistic.We're talking easy protein sources, fiber-rich foods, fruits and vegetables, freezer staples, carbohydrates, snacks, and the convenience foods I have absolutely no problem recommending.Because you don't need a cart full of expensive “health foods” or a perfectly meal-prepped refrigerator to nourish yourself well on a GLP-1. You need foods you enjoy, foods you'll actually eat, and options that make taking care of yourself easier when your appetite, schedule, and energy aren't always predictable.In this episode, you'll learn:What to buy at the grocery store while taking a GLP-1The protein foods I recommend keeping on handEasy options for days when your appetite is lowFiber-rich foods that can support your overall nutrition and digestive healthWhy frozen fruits and vegetables absolutely countMy favorite freezer and pantry staples for quick mealsWhy carbohydrates still belong in your grocery cartHow convenience foods can make healthy eating more sustainableHow to shop for your actual life instead of the imaginary week where you cook every meal from scratchHow to build a grocery cart that makes balanced eating easierWhether you're brand new to a GLP-1 or simply tired of overthinking every trip to the grocery store, consider this your realistic GLP-1 grocery shopping guide.

Nobody blinks when a doctor says you'll be on blood pressure medication for the rest of your life. Say the same sentence about an antidepressant, or Zepbound, and responses are quite different. This episode digs into deprescribing, the fast-growing clinical movement around when and how to stop medications, and asks why some "forever drugs" get a cultural pass while others get moralized. In this episode we will:Separate the real clinical debate around antidepressant tapering from the online discourseTake on the GLP-1 stigma directly, with two 2024 JAMA Internal Medicine studies that found no elevated depression or suicidality risk, and ask why "you may need this forever" reads as scandal here but shrug everywhere elseSit with the RLS story, where the science just ran the opposite direction: 2025 AASM guidelines downgraded dopamine agonists after mounting evidence of augmentation, a drug-induced worsening of symptoms, making deprescribing here the conservative, evidence-driven move, not the fringe oneAsk why hypersomnia drugs generate almost zero cultural friction at all, and what that quiet exception reveals about the other threeLand on what actually predicts whether a "forever medication" gets treated as a fact of chronic disease or a personal failing — and why RLS should make you distrust any tidy answer to that question, including this episode'sTo find out more about this week's podcast sponsor Fitnexa and their SomniPods 3, please use the following link https://go.fitnexa.com/egVvZ9 and use the code DRCHRIS10 for $10 dollars off your order.Original intro music Vigilanteology by Abhinav Singh (copyright 2026) Original outro music Vigilanteology (reprise) by Abhinav Singh (copyright 2026)Produced by: Maeve WinterMusic by: Dr. Abhinav Singh (@sleep_vigilante), all rights reservedMoreTwitter: @drchriswinterIG: @drchriwinterThreads: @drchriswinterBluesky: @drchriswinterThe Sleep Solution and The Rested ChildThanks for listening and sleep well!

GLP-1 medications are everywhere right now, and not just because people are losing weight. We're starting to see something far more interesting for addiction medicine: semaglutide may reduce alcohol cravings and heavy drinking, and early data hints it could influence other compulsive behaviors too. I recorded this talk after giving it as a lecture to my colleagues, and it's one I've wanted to share for a long time because the science is moving fast and the clinical questions are piling up.We walk through what GLP-1 drugs actually are, how gut hormones like GLP-1 and GIP shape appetite, digestion, and glycaemic control, and why side effects like nausea and bloating are so common. I also clear up the most confusing practical point patients run into: Ozempic versus Wegovy and Mounjaro versus Zepbound are often the same molecules labelled for different indications, and insurance coverage usually follows those rules.Then we get into the addiction evidence. I review three recent randomized controlled trials from 2025 to 2026 studying semaglutide for alcohol use disorder, including injectable and oral versions. The results aren't magic, but they're meaningful: fewer drinks on drinking days, fewer heavy drinking days, and lower craving scores compared with placebo, plus secondary findings that raise new research questions about nicotine and cannabis. Finally, I share two de-identified patient cases that show why GLP-1s can be a game-changer for some people and only a small nudge for others, especially when depression, grief, anxiety, or PTSD is the true engine behind drinking.If this helped you think differently about recovery tools, subscribe, share the show with a colleague or friend, and leave a review so more people can find it.To contact Dr. Grover: ammadeeasy@fastmail.com

One month into the Medicare GLP-1 Bridge program, I've learned that getting approved is less complicated once you understand the pathway. But there are several important details that can cause delays if you don't know what to look for. In this episode, I walk you through what I've learned from helping patients navigate the Medicare GLP-1 Bridge during its first month. We cover who qualifies, which medications and formulations are included, when you may need to use Medicare Part D instead, and what your doctor, pharmacy, and you need to do to keep the process moving. I'll also explain why your current BMI may not be the BMI that matters, why the pharmacy claim needs to happen before the prior authorization, and why staying engaged with both your pharmacy and doctor's office can make a difference. And once you actually get your medication, I shift the conversation to what you should be doing to maximize your results, including getting adequate protein, moving your body, strength training, and staying engaged with your medical team. If you're trying to navigate the Medicare GLP-1 Bridge program for yourself or a loved one, this episode will help you understand the process and the questions you need to ask. Episode Highlights: ● What the Medicare GLP-1 Bridge program is and how it differs from Medicare Part D ● The three main eligibility pathways for the Bridge program ● Why your BMI when you started GLP-1 therapy may matter more than your current BMI ● When certain medical conditions may require you to use the regular Medicare Part D pathway ● Why having eligible Medicare Part D coverage matters ● Which GLP-1 medications and formulations are included in the Bridge program ● Why the correct Zepbound formulation matters ● What your pharmacy needs from your Medicare information ● Why the pharmacy claim needs to happen before the prior authorization ● How to follow up when your prescription seems stuck in the process ● What to focus on once you actually receive your medication ● Why protein, exercise, strength training, and medical follow-up remain important ● What we currently know about what happens when the Bridge program ends   Connect with Dr. Alicia Shelly Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Not all weight loss medications are created equal, and picking the right one isn't as simple as choosing whatever's trending. In this episode, Lisa Oldson, MD walks through the framework she uses in her practice to decide which weight loss medication is right for each patient. She starts with other health conditions like sleep apnea, heart disease, diabetes, migraines, and fatty liver disease, then moves through safety considerations, cost, and how much weight loss someone actually needs. Whether someone prefers a shot or a pill is always a consideration. Using a real patient case, Dr. Lisa breaks down how GLP-1 medications like Zepbound (tirzepatide) and Wegovy (semaglutide), and other meds (like Qsymia and Foundayo) get matched to the right person. She also explains why medication for excess weight is legitimate, evidence-based chronic disease treatment, and not "cheating." This medication episode wouldn't be complete without an update on retatrutide, the "Triple G," next-generation medication making headlines with over 28% weight loss in recent trials.Grab the free worksheet that goes with this episode: https://www.smartweightlosscoaching.com/smart-weight-loss-coaching-podcast-worksheet-170Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also, we'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.The Smart Weight Loss Coaching Podcast is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication.

Oil Reserves taking a hit. Finally getting to the recent high profile earnings. Market Top Calls (again). ALL TIME HIGHS – Then some consolidation (then highs again). Situational Awareness Update. SpaceX Bounces… PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); Follow John S. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Oil Reserves taking a hit - Getting to the recent high profile earnings - Market Top Calls (again) Markets - ALL TIME HIGHS - Then some consolidation - Lets round out earnings - Situational Awareness Update - SpaceX Bounces... Etsy - Layoffs With Better Numbers - Etsy is cutting about 220 jobs, or 12% of its workforce. - Management said the cuts were not primarily about cost savings or AI. ----- CEO Kruti Patel Goyal stated the restructuring aims to simplify the organization, remove management layers, and speed up decision-making to better compete against massive rivals like Amazon, Temu, and TikTok Shop - Q2 revenue was about $668 million and core marketplace sales improved. - Etsy also authorized another $2 billion share buyback. - Comes after selling Depop to eBay for about $1.4 billion. Polysilicon - Tariffs Plus Price Floors - U.S. policy adds a 15% tariff and minimum import prices on polysilicon and solar products. - Goal is to protect domestic production from low-cost foreign competition. - U.S. share of global polysilicon capacity fell from about 50% in 2005 to under 2% in 2024. - First Solar and T1 Energy jumped on the announcement. ---- The same playbook - rinse and repeat Chipotle - Salmonella Returns - Minnesota officials linked a salmonella outbreak to jalapenos served at Chipotle. - Chipotle removed the affected pepper supply and switched growers. - Shares fell roughly 8%-10% as investors remembered the company's earlier food-safety problems. - This is on top of the lettuce situation with Sweetgreen- look at  STOCK CHART FOR SG Michael Burry - Calling a Major Top - Michael Burry says the market may be near a "major top." - Warned of the possibility of a 1987-style market drop. - He is short names including Nvidia, Palantir, Tesla and semiconductor stocks. - Main concern is stretched valuations and crowded trades unwinding quickly. - This may be the 100th top he has called since the GFC ---- NVIDIA TURNS GPUs INTO AN ASSET CLASS - Nvidia signed preliminary agreements with Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs and KKR to mobilize more than $500 billion for AI infrastructure. - The Wall Street firms would create dedicated pools of capital to finance Nvidia-based data centers and compute infrastructure at what Nvidia calls attractive rates for customers. - Jensen Huang: “This is really the first time that technology chips have become an investable asset class.” Nvidia says the compute assets now generate revenue and can increasingly be financed like infrastructure. - Nvidia could backstop as much as 25% of individual investments on a case-by-case basis - potentially up to about $125 billion if applied across the full program. STRATEGIC PETROLEUM RESERVE BREAKS 300 MILLION - The Strategic Petroleum Reserve fell by 6.1 million barrels to 298.7 million barrels for the week ended Aug. 7 - below 300 million for the first time since January 1983. - The SPR started 2026 around 415 million barrels, meaning more than 100 million barrels have already come out this year as releases were used to offset disruptions from the Iran conflict. - The reserve's authorized storage capacity is roughly 714 million barrels, leaving current inventories at about 42% of capacity. - Oil on the rise last week Earnings and such Toyota - Big Buyback, Better Outlook - Toyota raised its annual operating-profit forecast 13%, helped by the weaker yen. - Announced a share buyback worth up to $6.3 billion. - Quarterly operating profit still fell 9%, hurt by China weakness and higher Middle East-related costs. McDonald's - Value Problem - U.S. same-store sales rose just 0.8%, below expectations and well below last year's 2.5% growth. - Management blamed weak execution of value promotions and fewer digital deals. (and probably because everyone is taking weight loss drugs - see above) - Lower-income customer traffic remains a major pressure point. - McDonald's is bringing back more digital offers and loyalty promotions to drive traffic. Eli Lilly - Weight-Loss Machine - Lilly crushed Q2 expectations as Mounjaro and Zepbound drove most of the growth. - Mounjaro sales hit $9.94 billion; Zepbound brought in $4.93 billion. - Raised 2026 revenue guidance to $85-$87 billion. - Verzenio, its major breast-cancer drug, remains one of Lilly's biggest non-obesity products. - Lilly continues widening its lead over Novo Nordisk in the obesity-drug market. Disney - Parks Keep Printing Money - Quarterly adjusted EPS rose 28% to $2.06, beating the $1.86 estimate. - Parks and experiences revenue increased 10% to nearly $10 billion. - Global park attendance grew 4%. - Disney is selling its 50% stake in A+E Networks to Hearst for an estimated $1.2 billion. Oil - OPEC Adds Barrels, Maybe - OPEC+ agreed to raise September production targets by another 188,000 barrels per day. - The increase completes the rollback of a 1.65 million-barrel-per-day supply cut dating back to 2023. (In other words - planned so not a surprise) - Actual supply remains constrained because several producers are already pumping below quota. - Any normalization around the Strait of Hormuz could suddenly make OPEC+'s additional barrels much more important. Berkshire Hathaway - Greg Abel Starts Spending - Q2 operating earnings rose 16% to about $13 billion. - Berkshire bought $23.5 billion of stocks and sold just $3.7 billion - its first quarter as a net stock buyer in 14 quarters. - Bought back $4.5 billion of Berkshire shares, versus only $235 million in Q1. - Cash dropped from roughly $380 billion to $365 billion as Abel starts putting the massive cash pile to work. - Important shift: Buffett is still chairman, but this is one of the clearest signs yet of how Greg Abel may allocate capital differently as CEO. Situational Awareness - Nearly Blows Up, Investors Want Back In - The fund lost 67% in July after leveraged AI bets collapsed and forced a major stock sale to Citadel. - Despite the blowup, Situational Awareness was still up about 80% for 2026 because of huge earlier gains. - Bloomberg says Silicon Valley investors are already asking to put more money into the fund. - Situational Awareness is currently telling prospective investors it is not accepting new capital. - The fund has also continued making large private investments even after the near-collapse. --- Most recent was a $400B ---- There is some talk that Citadel made out like a bandit on the rescue Mercedes AMG - The Car Literally Brands You - Two Mercedes AMG owners filed a class-action lawsuit claiming the metal AMG logo embedded in the seat becomes dangerously hot in the sun. - One driver says he suffered first- and second-degree burns, with a dermatologist describing the injury as "AMG inscribed." - The lawsuit wants Mercedes to cover damages and remove the metal logos from affected vehicles. - Hard to beat this one: pay AMG money and get the logo branded into your back. Europe's Drought - History Starts Popping Out - Extreme drought and low river levels are exposing things that have been underwater or hidden for decades or centuries. - In Serbia, sunken German World War II warships have reappeared in the Danube. - In Britain, dry ground revealed outlines of medieval buildings; mammoth remains and ancient structures have also surfaced elsewhere. - Serious drought story, but visually one of the strangest side effects of the summer. Golden Toilet - $6 Million Flush - The 18-carat gold toilet was ripped out of Blenheim Palace in a five-minute raid and has never been recovered - but there is a conviction. - Prosecutors used phone data, forensic evidence and planning activity to link the gang to the theft. - One defendant had cased the palace beforehand and photographed entry points; another man had already pleaded guilty and admitted helping move the stolen gold. - Prosecutors believe the 98-kilo toilet was quickly cut up or melted down and sold as gold. - So the conviction was based on evidence of the robbery and disposal - not on recovering the actual toilet. Final Follow Up SpaceX - Space Junk Smashes Into the Moon - A dead SpaceX Falcon 9 rocket stage crashed into the moon at about 5,400 mph after drifting through space since January 2025. - The roughly 4-ton, school-bus-size object kicked up a lunar dust plume that astronomers detected from Chile. - The impact was accidental - solar activity and gravity gradually pushed the abandoned rocket stage onto a collision course. - NASA and SpaceX are now discussing ways to prevent future lunar crashes as more hardware heads toward the moon. - NEED Space garbage Trucks - something we have discussed on show for years (see next) Space Garbage Trucks - This Is Becoming a Business - Astroscale is building spacecraft designed to inspect, capture and remove dead satellites and other orbital debris. - Its ADRAS-J mission demonstrated close approach and inspection of a large piece of existing space junk - a key step before actually grabbing and removing debris. - ClearSpace is developing similar debris-removal spacecraft, including missions designed to rendezvous with and capture abandoned rocket hardware. - The business model is basically orbital towing: governments and satellite operators pay to remove dangerous junk or service aging spacecraft. - With tens of thousands of tracked objects already in orbit, "space sanitation" could become a real infrastructure business.   Love the Show? Then how about a Donation? PayPal.Donation.Button({ env: 'production', hosted_button_id: 'JJJHP2GDEJC7J', image: { src: 'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt: 'Donate with PayPal button', title: 'PayPal - The safer, easier way to pay online!' } }).render('#donate-button-2'); THE CLOSEST TO THE PIN for SpaceX (SPCX) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!   FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Nancy apologized for making the staff meeting go long yesterday. Karly texted and thanked Joey during the meeting because she thought he was trying to wrap things up so everyone could get on with their day. Joey shared that his mom, Babs, saw his "summer fit" picture and immediately asked if he was taking Zepbound. He said nope, just diet and exercise, which led to a conversation about how common weight loss drugs have become. Nancy said her son refuses to sleep in the guest room during their home renovation because he thinks the antique beds are haunted. The furniture came from her great-grandmother's old hotel, but he's convinced there are ghosts involved and plans to sleep on the couch instead. The show got into the crazy Penn State cocaine ring story involving fraternity members who allegedly had pledges helping package and sell drugs. Joey immediately turned it into a dramatic movie trailer. Joey and Nancy talked about "after-call ads," where certain apps can pop up advertisements the second you hang up a phone call. That turned into a discussion about all the random places ads have invaded, including gas pumps, rideshares, streaming services, and airport security lines. Hot Tea: Hayden Panettiere's mom spoke publicly after Hayden's passing and said she never approved of Hayden's boyfriend. Lainey Wilson landed her first comedy role on Leanne, starring East Tennessee favorite Leanne Morgan. And a man in Norway got fined nearly $7,000 for waking up a sleeping polar bear with a foghorn. Nancy was completely over refrigerator shopping after discovering modern fridges now come with cameras, grocery tracking, talking door alerts, and giant cocktail ice makers. She finally hired an appliance specialist because the choices were overwhelming. The show watched a viral clip of two Detroit TV anchors arguing off-camera and compared it to one of their own awkward radio moments. Joey brought up the time Nancy kept correcting him while he was trying to talk about the Budweiser Clydesdales. Lucky 7 for $50 to Old South Candy Joey admitted he has a weird rule about driving. If he sees someone he knows on the road, he refuses to pass them and tries not to be seen. His nightmare came true when a pastor spotted him at a stoplight flossing his teeth like his life depended on it. The show gave away a chance to ride Dollywood’s new Night Flight Expedition coaster with them. Listeners text FLIGHT to 865-656-9485. Joey and Nancy say 5 people's names on the air. The first of those people to call us wins. What Makes You Special? I'm a Foley Artist! See omnystudio.com/listener for privacy information.

Nancy apologized for making the staff meeting go long yesterday. Karly texted and thanked Joey during the meeting because she thought he was trying to wrap things up so everyone could get on with their day. Joey shared that his mom, Babs, saw his "summer fit" picture and immediately asked if he was taking Zepbound. He said nope, just diet and exercise, which led to a conversation about how common weight loss drugs have become. Nancy said her son refuses to sleep in the guest room during their home renovation because he thinks the antique beds are haunted. The furniture came from her great-grandmother's old hotel, but he's convinced there are ghosts involved and plans to sleep on the couch instead. The show got into the crazy Penn State cocaine ring story involving fraternity members who allegedly had pledges helping package and sell drugs. Joey immediately turned it into a dramatic movie trailer. Joey and Nancy talked about "after-call ads," where certain apps can pop up advertisements the second you hang up a phone call. That turned into a discussion about all the random places ads have invaded, including gas pumps, rideshares, streaming services, and airport security lines. Hot Tea: Hayden Panettiere's mom spoke publicly after Hayden's passing and said she never approved of Hayden's boyfriend. Lainey Wilson landed her first comedy role on Leanne, starring East Tennessee favorite Leanne Morgan. And a man in Norway got fined nearly $7,000 for waking up a sleeping polar bear with a foghorn. Nancy was completely over refrigerator shopping after discovering modern fridges now come with cameras, grocery tracking, talking door alerts, and giant cocktail ice makers. She finally hired an appliance specialist because the choices were overwhelming. The show watched a viral clip of two Detroit TV anchors arguing off-camera and compared it to one of their own awkward radio moments. Joey brought up the time Nancy kept correcting him while he was trying to talk about the Budweiser Clydesdales. Lucky 7 for $50 to Old South Candy Joey admitted he has a weird rule about driving. If he sees someone he knows on the road, he refuses to pass them and tries not to be seen. His nightmare came true when a pastor spotted him at a stoplight flossing his teeth like his life depended on it. The show gave away a chance to ride Dollywood’s new Night Flight Expedition coaster with them. Listeners text FLIGHT to 865-656-9485. Joey and Nancy say 5 people's names on the air. The first of those people to call us wins. What Makes You Special? I'm a Foley Artist! See omnystudio.com/listener for privacy information.

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he's right, it could completely change access to obesity treatment in America.But getting there may depend on something most patients have never heard of: the global peptide manufacturing supply chain.In this episode of The Weekly Dose from On The Pen, Dave Knapp, Man on the Mounjaro, breaks down one of the biggest weeks in GLP-1 and obesity medicine news, including the surprising role of Chinese pharmaceutical manufacturer WuXi AppTec, which Bloomberg described as having a “GLP-1 chokehold” while U.S. policymakers wrestle with reducing America's dependence on Chinese biotechnology.We also dig into one of the strangest GLP-1 stories of the year. Amylyx Pharmaceuticals just reported positive Phase 3 results for avexitide, a GLP-1 receptor antagonist, meaning it actually BLOCKS GLP-1. The drug reduced serious hypoglycemic events by 55% in patients with post-bariatric hypoglycemia, a debilitating condition that can occur after gastric bypass surgery.Then we get personal.Online personality Clavicular recently described becoming apathetic while taking a high dose of retatrutide, renewing the conversation around GLP-1 medications, anhedonia, emotional blunting, dopamine and reward signaling. Dave has firsthand experience with anhedonia during GLP-1 treatment and previously discussed that experience as part of coverage on the Today Show.At what point does turning down food noise start turning down everything else?We also examine Serena Williams' return to professional tennis while openly using Zepbound (tirzepatide) and the growing debate over whether GLP-1 medications could ever be considered performance-enhancing drugs in professional sports.Plus, new research suggests GLP-1 medications and significant weight loss may improve testosterone levels and fertility markers in men with obesity-related low testosterone, raising important questions about metabolic health, hypogonadism and when testosterone replacement therapy may or may not be appropriate.In this episode:

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Do you actually know the difference between a rough night's sleep and a real sleep disorder?Most people use the word "insomnia" for both, but the line between them is a lot more specific than it sounds — and knowing where that line sits can change how someone approaches their own sleep struggles entirely.That's exactly what this episode digs into, with Dr. Muhammad Usama returning to the show after a prior conversation on Zepbound and sleep apnea. He's triple board-certified in sleep and obesity medicine, practices at MultiCare Health System in the greater Seattle area, and serves as an adjunct clinical professor of medicine at A.T. Still University School of Osteopathic Medicine. His clinical and research work centers on the intersection of obstructive sleep apnea, obesity, and cardiometabolic health, with a particular focus on GLP-1 therapies like tirzepatide.This time, the conversation turns to insomnia itself: what actually qualifies as chronic insomnia, why it happens, and what treatment options genuinely move the needle versus which ones just create the illusion of help.Topics discussed:When Does Insomnia Stop Being Normal?The Switch That Turns Short-Term Insomnia Into Chronic InsomniaIs Insomnia Genetic? The Nature vs. Nurture AnswerChronic Insomnia: Why CBT-i, Not Sleep Hygiene, Is the First-Line TreatmentHow to Actually Access CBT-i (No Therapist Couch Required)Do Sleep Medications Actually Work? The Research Says Not MuchAcute Insomnia: How Early Intervention Prevents It From Becoming ChronicDoes Melatonin Actually Help With Sleep? What It's Really ForDo Sleep Supplements Like Magnesium Actually Work?Alcohol and Marijuana for Sleep: Do They Actually Help—or Hurt?Chronic Insomnia: When to Get Evaluated and What Actually WorksInsomnia is far more common, and far more treatable, than most people realize. Between understanding the difference between acute and chronic, recognizing the habits that quietly turn one into the other, and knowing which treatments actually hold up under research, this episode covers a lot of ground that can change how someone approaches their own sleep for good. If sleep has been a struggle for months, it's worth getting evaluated rather than just living with it — this episode is a great place to start.Connect with Dr. Usama:LinkedIn: Muhammad Usama, MD FACP DABOMInstagram: sleepwarriormd  Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Feeling like you're doing everything “right” on your GLP-1 but still not seeing the results you expected?You're not alone.As a Registered Dietitian who specializes in GLP-1 medications, I've worked with hundreds of people taking Ozempic, Wegovy, Mounjaro, and Zepbound—and I continue to see the same nutrition mistakes come up again and again.The good news? Most of them are completely fixable.In this episode, I'm breaking down the seven biggest nutrition mistakes I see people make while taking a GLP-1, why they happen, and the simple changes that can make a big difference in how you feel and the progress you're making.Whether you're just starting your GLP-1 journey or you've been taking your medication for months, this episode will help you focus on what truly matters—and let go of the nutrition myths that may be holding you back.In this episode, you'll learn:The most common nutrition mistakes I see people make on GLP-1 medicationsWhy eating too little can actually work against your goalsHow waiting too long to eat can make it harder to meet your nutrition needsWhy protein and fiber deserve a bigger role in your mealsHow hydration affects energy, digestion, and overall healthWhy one “off” meal doesn't ruin your progressHow perfectionism can become one of the biggest barriers to long-term successThe mindset shifts that help you build sustainable habits while taking a GLP-1If you've ever wondered “Why isn't my GLP-1 working?”, “Am I eating enough?”, or “What should I actually focus on?”, this episode is for you.Podcast with Weight & Measure on Apple and Spotify

What happens to eating disorder recovery when the culture around you starts celebrating weight loss again? In this deeply personal solo episode, Dr. Marianne continues sharing her eating disorder recovery story and talks about something that has surprised her: the return of body insecurities during the Age of Ozempic. After recovering from a decades-long history of anorexia, binge eating disorder, orthorexia, and bulimia, she rarely spends much time thinking about her body size. But the rise of Ozempic and other GLP-1 medications like Zepbound and Wegovy has changed the cultural conversation around weight, thinness, and fat bodies. During the height of the body diversity movement, living in a larger body felt different. Plus-size clothing became more visible. Larger bodies appeared in advertising. Conversations about weight stigma, fatphobia, body neutrality, and fat liberation entered the mainstream. Now, many of those gains seem to be disappearing as celebrities become smaller, plus-size departments vanish from stores, and thinness once again becomes something we're expected to pursue. When Eating Disorder Recovery Meets the Age of Ozempic Dr. Marianne shares what it's like to encounter old eating disorder and body image thoughts after years of recovery. Sometimes those thoughts arrive unexpectedly: Look at that celebrity. They did it. Why can't I? Having that thought doesn't mean eating disorder recovery has failed. Recovery doesn't necessarily erase decades of conditioning around weight and body size. Instead, it can help us recognize internalized weight bias when it resurfaces and decide whether we want to listen to it. Dr. Marianne also discusses an important distinction: wanting a smaller body isn't necessarily the same thing as wanting relief from anti-fat bias. Sometimes the thought, Life would be easier if I were thinner, reflects a painful reality about how fat people are treated rather than a genuine desire to change one's body. The World Is Getting Smaller for Fat People Anti-fat bias doesn't exist only in our thoughts. It shows up in the physical world. Plus-size clothing departments have disappeared from many stores, forcing people in larger bodies to shop online. Airplane seats continue to create accessibility barriers for larger passengers. Cars, restaurant booths, waiting-room chairs, theaters, and other public spaces frequently fail to accommodate body diversity. The message can become impossible to ignore: if the world won't make more space for you, you're expected to make yourself smaller. Dr. Marianne explores the mental health toll of repeatedly navigating environments that weren't designed for your body. Constantly wondering whether a seat will fit, whether a store carries your size, or whether a healthcare provider will blame your symptoms on weight creates an enormous cognitive and emotional burden. Defending the Right to Be Fat Dr. Marianne shares a recent dream in which she found herself defending her fatness to another person. When she woke up, she realized how closely the dream reflected the experience of living in a larger body today. Fat people often have to defend their right to exist without pursuing intentional weight loss. They may have to advocate for appropriate healthcare, accessible seating, clothing, travel accommodations, and the basic right to occupy space without apology. That emotional labor takes energy. For neurodivergent people, the burden can become even greater. Autistic people and ADHDers may already expend significant energy navigating sensory needs, executive functioning, uncertainty, masking, and environments that weren't designed for neurodivergent nervous systems. When neurodivergence intersects with anti-fat bias and other forms of marginalization, the cumulative mental health toll can become significant. Internalized Weight Bias Doesn't Mean You've Failed at Recovery Eating disorder recovery happens in the real world, not in a protected bubble. You can appreciate your body and still feel hurt by weight stigma. You can reject diet culture and feel grief when plus-size clothing disappears. You can practice fat acceptance and still have moments when you wonder whether life would be easier in a smaller body. Those experiences don't erase recovery. Sometimes what looks like body dissatisfaction is actually grief, anger, exhaustion, or a desire to move through the world without constantly having to advocate for your right to belong. Dr. Marianne shares the question that helps her separate internalized weight bias from her own values: Do I actually want a different body, or do I want a different world? Related Episodes How a Part of Me Wanted to Take a Weight-Loss Drug on Apple & Spotify. My Eating Disorder Recovery Story on Apple & Spotify. Finding Liberation-Focused Eating Disorder Support If the Age of Ozempic has stirred up old body image struggles, eating disorder thoughts, or internalized weight bias, you don't have to navigate those experiences alone. Finding an eating disorder therapist or provider who understands weight stigma can make a profound difference. Liberation-focused, trauma-informed, neurodivergent-affirming eating disorder treatment can create space to examine these experiences without making weight loss the goal. If you'd like to work with Dr. Marianne, she provides eating disorder therapy in California for adolescents and adults navigating anorexia, bulimia, binge eating disorder, ARFID, body image concerns, and neurodivergence. If you live elsewhere, Dr. Marianne also offers consultations and coaching for individuals, families, and professionals. Learn more about working with Dr. Marianne at drmariannemiller.com.

The Wall Street Journal reports that major Gulf energy exporters, including countries such as Saudi Arabia and the UAE, are increasingly concluding that Iran may retain effective control over the Strait of Hormuz for the foreseeable future. While they dislike this outcome, many see it as preferable to a return to full-scale war. Axios reports that, for only the third time in U.S. history, women now hold more jobs than men in the American workforce. As of February 2026, there were about 200,000 more women employed than men, according to federal labor data highlighted by Indeed's Hiring Lab. Fortune reports that women now hold more jobs than men in the U.S. workforce for only the third time in history, but argues that the bigger story is not women entering the workforce. Instead, it's that men are increasingly leaving or not entering the labor force. Psychology Today explores a growing phenomenon sometimes called“Ozempic divorce”: reports that some marriages and long-term relationships experience strain or even break down after one partner achieves significant weight loss using GLP-1 medications such as Ozempic or Zepbound. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org

Wondering how much protein you actually need while taking Ozempic, Wegovy, Mounjaro, or Zepbound?You've probably heard over and over again that you need to "eat more protein" on a GLP-1—but how much do you really need? Do protein shakes count? Can you eat too much protein? And is it true that your body can only absorb 30 grams at a time?In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna answers the most common questions she hears from clients about protein and GLP-1 medications. You'll learn why protein is so important during weight loss, how protein supports muscle health, common myths to stop believing, and practical strategies to help you reach your protein goals—even when your appetite is low.Whether you're just starting your GLP-1 journey or you've been taking your medication for months, this episode will help you feel more confident about nourishing your body without obsessing over numbers.In this episode, you'll learn:Why protein is one of the most important nutrients while taking a GLP-1How protein helps support muscle during weight lossHow protein needs are determined—and why there isn't one perfect number for everyoneThe biggest protein myths I hear as a Registered DietitianWhether protein shakes "count"Can your body really only absorb 30 grams of protein at a time?Easy ways to increase your protein intake when your appetite is lowMy favorite high-protein foods for breakfast, lunch, dinner, and snacksThe biggest protein mistakes I see people make on GLP-1 medicationsIf you've ever searched "How much protein should I eat on Ozempic?", "How much protein do I need on Wegovy?", or "Do I need protein shakes on a GLP-1?", this episode is for you.

Our kidneys do an incredible job filtering our blood every hour of every day. Most of us have two kidneys, and each one has about a million microscopic filters called glomeruli. Unlike the filters in our HVAC system, though, these filters cannot be replaced. But they do their work so well and unobtrusively that most of us don't even think about our kidney function. Although 37 million Americans have kidney trouble, the majority are unaware of their situation. Two tests could reveal how well the kidneys are working. What are they, and how often should you ask about them? At The People's Pharmacy, we strive to bring you up‑to‑date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, August 8, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on August 10, 2026. What Are the Two Tests That Reveal Kidney Trouble? Chronic conditions like high blood pressure and diabetes put a strain on the kidneys. They are very common problems that signal the need for kidney function monitoring. Our guest expert, Dr. Samir Parikh, suggests that all of us should know our numbers. One is derived from the level of creatinine in the blood. This is normally part of a basic metabolic panel. Usually, the panel results will include a number for the estimated glomerular filtration rate (EGFR) calculated from the value for blood creatinine. The other crucial test is a urine test for protein. Keeping Kidneys Healthy by Staying Properly Hydrated One of the simplest tactics to keep kidneys healthy is to provide them with enough liquid. We get some fluid from the food we eat, which may be one reason eating fruits and vegetables seems to be good for us. They are full of water! We also need to drink fluid, and plain water is probably the best choice. It would be smart to use thirst as a guideline and make sure to drink when thirsty. We do avoid overdoing water consumption, though, as overloading the kidneys with more fluid than they can handle is dangerous as well. Medicines That Are Hard on the Kidneys We mentioned to Dr. Parikh the experience of an older friend, a devoted runner, who discovered that taking ibuprofen after a run reduced the likelihood of having to get up overnight to urinate. He reminded us and our listeners that nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, celecoxib or meloxicam can be hard on the kidneys. That doesn't mean we shouldn't ever take such pain relievers, but perhaps we should try not to make it a habit. When we asked about other medicines that might be tough on the kidneys, he mentioned PPIs. Proton pump inhibitors such as omeprazole (Prilosec) or esomeprazole (Nexium) are often used to treat heartburn or other digestive symptoms. Regular use can put a strain on the kidneys, although the gastroenterologist recommending the medicine might not warn you of that side effect. We asked about environmental toxins and learned that heavy metals such as lead or arsenic can harm the kidneys along with other organs. We should make sure that the food we eat and the water we drink are not contaminated with such compounds. The Possible Benefits of Vitamin B Dr. Parikh has been studying how the kidneys respond to the B vitamin nicotinamide. The preliminary work he and his colleagues have done so far is promising. However, they have not conducted clinical trials to find out whether the vitamin could help people with early kidney disease. Because kidneys work so hard, they need a lot of energy to be produced by the mitochondria in their cells. Those mitochondria need NAD+ (nicotinamide adenine dinucleotide) to function at their best. Providing additional nicotinamide appears to help (Nature Reviews. Nephrology, Feb. 2020).  One to three grams a day appears to be safe and may be beneficial. Medications That Can Promote Kidney Health Some medicines initially developed for other conditions are proving to be helpful in treating kidney disease. In particular, these include diabetes drugs known as SGLT2 inhibitors like dapagliflozin (Farxiga) or empagliflozin (Jardiance). They help slow the decline of kidney function (New England Journal of Medicine, Nov. 4, 2022). GLP-1 agonists may also be familiar because they too are used to treat diabetes. Medications such as semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound) have made headlines as weight loss and diabetes meds, but they also can reduce the risk of kidney failure and other bad outcomes (Lancet. Diabetes & Endocrinology, Jan. 2025). The benefits of these types of drugs should give us hope that we can go from slowing the progression of kidney disease to stopping it in its tracks Taking Care of Your Kidneys We asked Dr. Parikh what we should be doing to care for our kidneys and keep them healthy. He urged us once again to know our numbers: most importantly, the numbers from the two tests we discussed, blood creatinine and urine protein. Other numbers that are important for kidney are our blood pressure and, for those with diabetes, HbA1c. In addition to paying attention to all those numbers, we need to embrace a lifestyle that will help keep them where they belong. That means following a heart-healthy diet, staying physically active and getting adequate sleep. This Week’s Guest Samir M. Parikh, M.D., FASN, is Professor of Internal Medicine and Pharmacology and Chair of Internal Medicine at the University of Texas Southwestern. He holds the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy, Sr., Chair in Molecular Nephrology. Dr. Samir Parikh, University of Texas Southwestern Listen to the Podcast The podcast of this program will be available Monday, August 10, 2026, after broadcast on Aug. 8. This week's podcast has additional information on a possible role for sodium bicarbonate (baking soda) for kidney function. We also discussed medical silos, and how that leads to gastroenterologists overlooking the kidney risks from PPIs. Also, what should prospective kidney donors consider? You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

P.M. Edition for Aug. 5. Seven-year-old Whatnot is gaining popularity among people drawn to its high-energy live auction sales on everything from fashion to trading cards. But as WSJ retail reporter Hanna Krueger discusses, some users say they're hooked even when they feel like they should walk away. Plus, progressive candidate Abdul El-Sayed clinched the Democratic senate nomination in a closely-watched race in Michigan. We hear from Journal reporter Terell Wright about what this means for the Democratic party's future. And Google shakes up the leadership of its AI operations as it struggles to keep pace with competitors' top models. Alex Ossola hosts. Whatnot, the Live Shopping App Where Some People Bid Until They're Broke  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Disney's third-quarter revenue was boosted by theme park visitors and Toy Story 5. And Eli Lilly posted higher revenue on continued GLP-1 demand. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to Season 7 of The Hormone Genius Podcast! We're kicking off this new season with a timely conversation about one of the most talked-about topics in medicine today: GLP-1 medications for weight loss. From Ozempic® and Wegovy® to Zepbound®, these medications have sparked excitement, controversy, and countless questions. Are they safe? Who are they for? Are they simply a shortcut, or could they be a powerful tool for improving long-term health? In this episode, Teresa breaks down the science behind GLP-1 medications, explaining how these naturally occurring hormones help regulate blood sugar, appetite, digestion, and metabolism. You'll learn how these medications were originally developed for diabetes, why they've become such a breakthrough in obesity treatment, and what the latest research tells us about their benefits beyond weight loss. Jamie guides the conversation using the B.R.A.I.N. framework, Benefits, Risks, Alternatives, Intuition, and Next Steps, to help listeners think critically and confidently when discussing treatment options with their healthcare provider. Together, we discuss: What GLP-1 medications are and how they work The difference between semaglutide (Ozempic®, Wegovy®) and tirzepatide (Zepbound®) Why obesity is now recognized as a chronic disease, not simply a lack of willpower The concept of "food noise" and how GLP-1 medications may reduce constant thoughts about food Potential benefits beyond weight loss, including improvements in diabetes, cardiovascular health, inflammation, and even emerging research on addiction Common side effects, safety concerns, and who may not be a good candidate The importance of preserving muscle mass with adequate protein intake and strength training How GLP-1 medications compare to alternatives such as lifestyle changes, metformin, and nutritional supplements Why these medications should be viewed as one tool within a comprehensive plan not a replacement for healthy habits Perhaps most importantly, this episode emphasizes the value of an individualized approach. There is no one-size-fits-all answer. The best treatment plan considers your medical history, goals, lifestyle, and values in partnership with a trusted healthcare professional. Whether you're curious about GLP-1 medications, considering them yourself, or simply want to better understand the science behind the headlines, this episode offers an evidence-based, balanced perspective to help you make informed decisions about your health. Join us as we launch Season 7 with one of the biggest conversations in modern medicine, and discover why understanding your hormones and metabolism is key to becoming your own Hormone Genius. Hormone Genius wants YOU to partner with us! PODCAST PARTNER: docs.google.com/forms/d/e/1FAIpQL…Q0iRgHqg/viewform MONTHLY SPONSOR: docs.google.com/forms/d/e/1FAIpQL…al5nkGyA/viewform BRAND PARTNER: docs.google.com/forms/d/e/1FAIpQL…d8-G5qaA/viewform Thank you to our podcast sponsors: We Heart Nutrition: 20% OFF CODE GENIUS Grazing Beauty Tallow: grazingbeauty.com 10% OFF Code HORMONEGENIUS Hormone Genius Perimenopause Program at www.hormonegenius.com Medical Disclaimer This podcast is intended for educational and informational purposes only and should not be considered medical advice. The information shared in this episode is not intended to diagnose, treat, cure, or prevent any disease. Always consult your qualified healthcare provider regarding any medical concerns or before making changes to your healthcare routine.

Andrew, Ben, and Tom discuss SpaceX falling 11% despite laying out an ambitious AI and Starlink roadmap including Grok 5 trained on internal SpaceX data by year-end, 1.4GW of current compute growing toward 10GW by end of 2027, deploying NVL72-designed data centers on the ground rather than in space, boots on the moon by 2028, and the goal of scaling launch cadence to one per day in 2027, SpaceX's decision to go exclusively with Nvidia sending AMD down 9% despite good results and CPU acceleration while Arista Networks jumped 14% on accelerating networking demand tied to Nvidia, CVS raising guidance and re-adding Zepbound to its formulary while publicly backing Eli Lilly with expanded GLP-1 support, Lilly beating on stronger-than-expected GLP-1 pricing, Disney rising 4% on parks strength and a TikTok short-form video partnership, Uber slipping despite record first-time user additions, and the JOLTS report showing softer job openings but likely not a signal Warsh will weigh.Join our live YouTube stream Monday through Friday at 8:30 AM EST:http://www.youtube.com/@TheMorningMarketBriefingPlease see disclosures:https://www.narwhal.com/disclosure

On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com   Transcript:  (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you're organizing: a fundraiser, walk, or local meetup Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It's your chance to share what you're doing and help others get connected! Full instructions are on the website. While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921.   Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip:   Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter" https://www.youtube.com/watch?v=nnSQS43Eil8   Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet." Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer:   XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time.   The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values.   The device needs further validation in diverse clinical settings and across large diabetic cohorts.   https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx   XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level < 3.9 mmol/L (70 mg/dL). The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C.   https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared.   The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal.   https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox..   XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years. These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women) Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems. And while the study says it's 37% higher for the younger group, the actual rate was still very low. As always, I'll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2.   https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir XX Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life. https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx XX Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year. https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/ XX The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program. Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes. The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress. The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions. https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/ XX Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump. Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott's dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year. Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month. https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/ XX Eli Lilly expands it's partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply XX Alex Cooper – the host of the top podcast Call her Daddy – announced she's been diagnosed with gestational diabetes.   "When I got this diagnosis, the first couple days, I was really hard on myself," the 31-year-old admitted. "It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it's me on an island." She says she found an online community that's been helping. In sharing her experience, she hoped it would alleviate the stress. https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis XX Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes. Check out all the charities and vote for your favorites – you've heard of so many of these I promise – at the link in the episode show notes, . https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact

Are you tired of working out endlessly and trying every generic diet, only to see zero results? What if the problem isn't your discipline, but a lack of information about your unique biology? In this episode of The Level Up Podcast, Paul Alex sits down with Dora Maria, a Bay Area native, UC Berkeley graduate, and former healthcare executive who spent 15 years within the medical system. Dora shares her incredible journey from growing up in a garage while her mother battled breast cancer, to reaching the peak of her career, only to find herself in the back of an ambulance at 39 years old. After struggling with pre-diabetes, a 50-pound weight gain, and uncontrolled hypertension, Dora realized that the traditional healthcare system is designed for surviving, not thriving. She took her health into her own hands, utilizing DNA testing and advanced lab panels to uncover exactly what her body needed. Dora breaks down the truth about popular weight loss trends, explaining why the Keto diet landed her in the ER with appendicitis, and why high-intensity workouts like Orange Theory were actually causing her body to hold onto fat. She also dives deep into the world of peptides, explaining the difference between weight loss GLPs (like Ozempic and Zepbound) and powerful longevity peptides (like BPC-157 and the Wolverine stack) for tissue regeneration and anti-aging. If you are a high-performing professional or entrepreneur looking to optimize your health, buy back your time, and finally get a customized plan that fits your DNA, this episode is a game-changer! Make sure to follow Dora on Instagram: @iamdoramaria Listen to The Level Up Podcast w/ Paul Alex: Available on Apple Podcasts and Spotify. Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you wondering if GLP-1 medications like Ozempic or Zepbound are right for you? In this episode of FAT LOSS SCHOOL, we're opening the classroom doors for GLP-1 School— practical, science-based lessons designed specifically for women over 50. GLP-1 medications have changed the conversation around weight loss, but they aren't magic. They are simply one tool. Whether you're already taking a GLP-1, considering one, or know someone who is, understanding how to protect your muscle, metabolism, and long-term health is essential. As a certified FASTer Way coach who has completed specialized training in GLP-1s and metabolic health, I'll explain what these medications do, what they don't do, and how to build healthy habits that support lasting fat loss. In This Episode You'll Learn: What GLP-1 medications are and how they work How GLP-1s reduce appetite and support weight loss The difference between weight loss and fat loss Why preserving muscle is critical after age 50 How much protein women should prioritize while taking a GLP-1 Why strength training becomes even more important during GLP-1 treatment The importance of hydration, fiber, and nutrient-dense foods How to avoid losing muscle along with body fat Why healthy habits are still the foundation of long-term success How the FASTer Way complements GLP-1 medications with nutrition, fitness, and accountability Key Takeaway GLP-1 medications can be incredibly helpful tools for the right person—but they work best when paired with healthy lifestyle habits. If your goal is to lose fat while protecting muscle, you'll need: Adequate protein Regular strength training Daily movement Proper hydration Quality sleep Consistent nutrition Ongoing coaching and accountability The medication may reduce your appetite, but your daily choices determine the quality of the weight you lose. Ready to Learn the FASTer Way? Whether you're using a GLP-1 medication, thinking about one, or simply want a sustainable approach to fat loss after 50, I'd love to coach you. Inside my FASTer Way to Fat Loss® program, you'll learn how to: Preserve lean muscle Improve metabolic health Build strength Prioritize protein Develop lifelong nutrition habits Create sustainable routines that continue working long after any medication ends Here is the link to join my next class for women over 50: https://www.fasterway.com/?aid=AMYBRYAN  Connect with Amy Join my free Facebook community for women over 50, subscribe to my newsletter, email me, schedule a discovery call, or grab a freebie here:  www.linktr.ee/amybryanfasterway If today's episode helped you better understand GLP-1 medications, please leave a review and share this episode with a friend who could benefit from this information.

The Cutting Edge #26 Are you currently taking a GLP-1 medication (like Ozempic, Wegovy, Mounjaro, or Zepbound) and planning for plastic surgery or general anesthesia? In this critical episode of The Cutting Edge Podcast, host Mel sits down with bariatric therapist Ashlyn Douglass-Barnes and board-certified plastic surgeon Dr. Omar Beidas to unpack the medical, psychological, and surgical risks every patient must know. If you are navigating weight loss surgery, post-bariatric skin removal, or GLP-1 therapy, this video explains why stopping your injection before surgery isn't optional—it could literally save your life.

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

Recent studies say that somewhere between 12 and 16 percent of Americans have used GLP-1s like Ozempic, Wegovy, or Zepbound. Many people who take these drugs report that the meds have fundamentally changed their relationship to food. Jason Diamond is a writer who covers food, men's fashion, and culture. Throughout his life he's had a complicated relationship with both food and medication, which played a big role in how he thought about whether or not, as a new dad, to start taking GLP-1s.  Jason's story in New York Magazine is “Eating With My Daughter and My Zepbound.” The Sporkful production team includes Dan Pashman, Emma Morgenstern, Andres O'Hara, Kameel Stanley, and Jared O'Connell. Right now, Sporkful listeners can get three months free of the SiriusXM app by going to siriusxm.com/sporkful. Get all your favorite podcasts, more than 200 ad-free music channels curated by genre and era, and live sports coverage with the SiriusXM app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.